Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681228 | 0.83 | TSHR (0.54) | ALDH1A1L3MBTL1MAPTLMNARAB9A | |
| SCHEMBL5022147 | 0.77 | GAA (0.50) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL20560160 | 0.75 | GAA (0.51) | KMT2AALDH1A1GAA | |
| SCHEMBL19388071 | 0.74 | POLB (0.68) | MEN1KMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL11436764 | 0.74 | KMT2A (0.53) | KMT2AALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL31656350 | 0.74 | TSHR (0.68) | KMT2AALDH1A1MAPTRAB9AGAA | |
| SCHEMBL6328388 | 0.74 | L3MBTL1 (0.55) | ALDH1A1L3MBTL1MAPTLMNAHPGD | |
| SCHEMBL8626261 | 0.74 | MEN1 (0.59) | MEN1KMT2AALDH1A1L3MBTL1MAPT | |
| SCHEMBL15625387 | 0.73 | GAA (0.46) | KMT2AGAAKDM4EPOLB | |
| SCHEMBL30447460 | 0.73 | PDK1 (0.58) | MEN1KMT2AALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119365192-A | Heteroaryl compounds as HPK1 inhibitors and methods of use thereof | 深圳市原力深湾创新药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4463150-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | MEN1 2249/4885KMT2A 2422/4885ALDH1A1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.